Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

diamedica therapeutics inc - DMAC

DMAC

Close Chg Chg %
8.05 -0.11 -1.30%

Open Market

7.95

-0.11 (1.30%)

Volume: 22.19K

Last Updated:

Dec 31, 2025, 10:28 AM EDT

Trade Now

Company Overview: diamedica therapeutics inc - DMAC

DMAC Key Data

Open

$8.02

 Day Range

7.90 - 8.02

52 Week Range

3.22 - 10.42

 Market Cap

$431.20M

Shares Outstanding

52.08M

 Public Float

23.18M

Beta

1.30

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.72

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

454.84K

  

DMAC Performance

1 Week
 
 -2.19%
 
1 Month
 
 -6.72%
 
3 Months
 
 13.86%
 
1 Year
 
 48.25%
 
5 Years
 
 -20.61%
 

DMAC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About diamedica therapeutics inc - DMAC

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DMAC At a Glance

DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Minneapolis, Minnesota 55305
Phone 1-763-496-5454 Revenue 0.00
Industry Biotechnology Net Income -24,444,000.00
Sector Health Technology Employees 28
Fiscal Year-end 12 / 2025
View SEC Filings

DMAC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.71
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.591
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.002

DMAC Efficiency

Revenue/Employee N/A
Income Per Employee -873,000.00
Receivables Turnover N/A
Total Asset Turnover N/A

DMAC Liquidity

Current Ratio 8.276
Quick Ratio 8.276
Cash Ratio 8.191

DMAC Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -48.642
Return on Equity -53.269
Return on Total Capital -59.535
Return on Invested Capital -52.95

DMAC Capital Structure

Total Debt to Total Equity 0.835
Total Debt to Total Capital 0.828
Total Debt to Total Assets 0.734
Long-Term Debt to Equity 0.582
Long-Term Debt to Total Capital 0.577
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Diamedica Therapeutics Inc - DMAC

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
24.00K 25.00K 30.00K 39.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
24.00K 25.00K 30.00K 39.00K
Depreciation
24.00K 25.00K 30.00K 39.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+14.29% +4.17% +20.00% +30.00%
Gross Income
(24.00K) (25.00K) (30.00K) (39.00K)
Gross Income Growth
-14.29% -4.17% -20.00% -30.00%
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
13.62M 13.98M 21.24M 26.64M
Research & Development
8.77M 7.84M 13.11M 19.06M
Other SG&A
4.86M 6.14M 8.13M 7.59M
SGA Growth
+7.45% +2.60% +51.95% +25.45%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(13.65M) (14.00M) (21.27M) (26.68M)
Non Operating Income/Expense
82.00K 353.00K 1.93M 2.27M
Non-Operating Interest Income
- - - 2.30M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(13.56M) (13.65M) (19.34M) (24.41M)
Pretax Income Growth
-10.59% -0.62% -41.69% -26.25%
Pretax Margin
- - - -
-
Income Tax
28.00K 28.00K 43.00K 30.00K
Income Tax - Current - Domestic
- - 28.00K 28.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.59M) (13.68M) (19.38M) (24.44M)
Minority Interest Expense
- - - -
-
Net Income
(13.59M) (13.68M) (19.38M) (24.44M)
Net Income Growth
-10.58% -0.62% -41.72% -26.12%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.59M) (13.68M) (19.38M) (24.44M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.59M) (13.68M) (19.38M) (24.44M)
EPS (Basic)
-0.6543 -0.5172 -0.5951 -0.605
EPS (Basic) Growth
+16.53% +20.95% -15.06% -1.66%
Basic Shares Outstanding
20.77M 26.44M 32.57M 40.40M
EPS (Diluted)
-0.6543 -0.5172 -0.5951 -0.605
EPS (Diluted) Growth
+16.53% +20.95% -15.06% -1.66%
Diluted Shares Outstanding
20.77M 26.44M 32.57M 40.40M
EBITDA
(13.62M) (13.98M) (21.24M) (26.64M)
EBITDA Growth
-7.45% -2.60% -51.95% -25.45%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 12.333
Number of Ratings 5 Current Quarters Estimate -0.193
FY Report Date 03 / 2026 Current Year's Estimate -0.756
Last Quarter’s Earnings -0.175 Median PE on CY Estimate N/A
Year Ago Earnings -0.684 Next Fiscal Year Estimate -0.88
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 5 4
Mean Estimate -0.19 -0.21 -0.76 -0.88
High Estimates -0.18 -0.19 -0.60 -0.74
Low Estimate -0.22 -0.22 -0.90 -1.05
Coefficient of Variance -11.95 -7.39 -15.89 -16.10

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Diamedica Therapeutics Inc - DMAC

Date Name Shares Transaction Value
Sep 5, 2025 Trill AB 7,058,066 Open market or private purchase of non-derivative security Non-derivative transaction at $5.91 per share 41,713,170.06
Sep 5, 2025 Trill AB 7,128,480 Open market or private purchase of non-derivative security Non-derivative transaction at $5.99 per share 42,699,595.20
Sep 5, 2025 Trill AB 7,136,713 Open market or private purchase of non-derivative security Non-derivative transaction at $6 per share 42,820,278.00
Sep 5, 2025 Trill AB 7,207,820 Open market or private purchase of non-derivative security Non-derivative transaction at $5.86 per share 42,237,825.20
Sep 5, 2025 Trill AB 7,255,992 Open market or private purchase of non-derivative security Non-derivative transaction at $5.96 per share 43,245,712.32
Sep 5, 2025 Trill AB 7,315,780 Open market or private purchase of non-derivative security Non-derivative transaction at $5.96 per share 43,602,048.80
Sep 5, 2025 Trill AB 7,654,045 Open market or private purchase of non-derivative security Non-derivative transaction at $6 per share 45,924,270.00
Sep 5, 2025 Trill AB 7,713,693 Open market or private purchase of non-derivative security Non-derivative transaction at $6 per share 46,282,158.00
Sep 5, 2025 Trill AB 7,764,465 Open market or private purchase of non-derivative security Non-derivative transaction at $6 per share 46,586,790.00
Feb 26, 2025 Daniel J. O'Connor N/A Opening Balance – Initial SEDI Report 0.00
Feb 26, 2025 Daniel J. O'Connor 64,242 Grant of options 0.00
Jan 6, 2025 James T. Parsons Director 4,287 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Diamedica Therapeutics Inc in the News